Quando Veronica Ciudad-Real foi diagnosticada no começo do ano passado com mieloma múltiplo, um câncer do sangue do qual ela nunca tinha ouvido falar, ela teve mais perguntas do que respostas. Aos 40 anos, ela era mais jovem do que a maioria das pessoas com essa doença.
Cuando Verónica Ciudad-Real recibió a principios del año el diagnóstico de mieloma múltiple, cáncer de la sangre del cual ella nunca había escuchado hablar, tuvo muchas preguntas y pocas respuestas. A sus 40 años, era más joven que la mayoría de las personas que sufren de esta enfermedad.
Preventing the formation of a sticky, web-like substance that can form in blood vessels after a stroke could protect the brain and lead to better outcomes for patients, studies in mice suggest. The research was reported in the Journal of Clinical Investigation and led by scientists at University of Utah Health.
SEATTLE — April 6, 2022 — Below are summaries of recent Fred Hutchinson Cancer Research Center research findings and other news. If you’re covering the American Association of Cancer Research’s annual meeting, April 8-13, see our list of Fred Hutch highlights for AACR and contact [email protected] for help setting up interviews with experts.
Most immunocompromised people with a blood cancer called multiple myeloma benefited from a third dose of COVID-19 vaccines, a promising sign after it was shown that two doses tended to not be sufficient for them. However, some people with multiple myeloma still remained vulnerable and may need a fourth dose or antibody treatments as restrictions lift and new variants emerge, according to a fast-tracked study in Cancer Cell.
Here are some of the latest articles that have been added to the Clinical Trials channel on Newswise.
Using a protein nanoparticle they designed, scientists at the University of Illinois Chicago have identified two distinct subtypes of neutrophils and found that one of the subtypes can be used as a drug target for inflammatory diseases.
The Gairdner Foundation has announced that Stuart H. Orkin, MD, is one of the 2022 Canada Gairdner Award laureates for seminal discoveries and contributions to biomedical science.
A new type of anti-clotting drug caused fewer bleeding incidents among patients with atrial fibrillation than the commonly prescribed apixaban, according to results from a head-to-head comparison of the two.
.jpg&width=400&height=400)
The drug tested, tranexamic acid (TXA), was given to patients at risk of bleeding or vascular complications. The study found that TXA did not increase deep vein clotting known as VTE, heart attack, non-hemorrhagic stroke, or other major vascular complication in the 30 days after surgery. In the study, half of 9,535 patients in 22 countries were randomly assigned TXA, half placebo. Patients were 45 years or older (average age 69 years); 44% of them were female.
A comprehensive look at all of the active clinical trials on new CRISPR-based genome editing therapies in 2022, and perspective on what is coming next.
In a new study from Vanderbilt University Medical Center, 10-second videos of white blood cell motion in the skin’s microvasculature greatly improved the prediction of which stem cell and bone marrow transplant patients would have a relapse of their blood cancer.
The researchers, who hope to continue developing the app, were undaunted by its lackluster performance. “That just means we need to work more on the app and try to improve it,” Collins says. “We’re working on another app that will be more sophisticated and will be compatible with Android and Mac iOS.”
The American College of Surgeons (ACS) STOP THE BLEED® Program is supporting efforts to help people in Ukraine learn the basics of the STOP THE BLEED® course.
Chimeric antigen receptor (CAR) T cells can be remarkably effective in treating leukemias and lymphomas, but there are no successful immunotherapies for neuroendocrine tumors (NETs) and gastrointestinal cancers (GICs) yet. Researchers at Penn Medicine have discovered that CAR-T cells directed to a tumor antigen, CDH17, a cell surface marker expressed on both NETs and GICs but also found on healthy tissues, eliminated GICs in several preclinical models without toxicity to normal tissues in multiple mouse organs, including the small intestine and colon. The results from this study, the first to target CDH17 in neuroendocrine tumors, suggest a new class of tumor associated antigens accessible to CAR-T cells in tumors but sequestered from CAR-T cells in healthy tissues.
A new study led by researchers at University of Utah Health details a novel mechanism that infectious bacteria use to quickly adjust to environmental stress. The discovery could help explain why certain types of common infections—such as urinary tract and bloodstream infections like sepsis—are hard to get rid of.
UCSF’s Division of Hematology-Oncology is welcoming Krishna Komanduri, MD, as division chief of Hematology-Oncology at UCSF Health. Komanduri is an international leader in the fields of hematology-oncology, transplantation, and cellular immunotherapy. He will start at UCSF on July 1.
Antiphospholipid syndrome (APS) is rare in children and known to cause inflammation and recurring, potentially fatal, blood clots. Researchers found that two-thirds of children with the autoimmune disease experienced additional symptoms not formally associated with APS, including low platelet counts, hemolytic anemia and livedo reticularis, a rash indicating abnormal blood flow to the skin. Investigators say the findings underscore the importance of creating pediatric-specific criteria for the diagnosis of APS.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right